Study Title
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)
Study Number
SCRI OP-1250-302
Enrollment status
Open
Categories
Breast, Metastatic
Study Summary
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Study Coordinator(s)
- Kimberley, 309-243-3618 ksinanan@illinoiscancercare.com
- Carrie, 309-243-3661 cgeoffroy@illinoiscancercare.com
- Jessica, 309-243-3615, jjones@illinoiscancercare.com